New Protein Biomarker Identified in Insulin Resistance

This article originally appeared here.
Share this content:
New Protein Biomarker Identified in Insulin Resistance
New Protein Biomarker Identified in Insulin Resistance

MONDAY, Oct. 5, 2015 (HealthDay News) -- Proteomic blood profiling has identified new circulating biomarkers for homeostasis model assessment of insulin resistance (HOMA-IR), according to a study published online Sept. 29 in Diabetes.

Christoph Nowak, B.M., B.Ch., from Uppsala University in Sweden, and colleagues used a novel high-throughput 92-protein assay to identify circulating biomarkers for HOMA-IR in two cohorts of 1,367 community residents without diabetes.

The researchers identified cathepsin D and confirmed six proteins (leptin, renin, interleukin-1 receptor antagonist [IL-1ra], hepatocyte growth factor, fatty acid binding protein 4, and tissue plasminogen activator [t-PA]) as IR biomarkers. There was a positive causal effect for IR on t-PA concentrations. IL-1ra and t-PA correlated with incident type 2 diabetes (hazard ratios, 1.28 and 1.30, respectively), while five-year transition to hyperglycemia was predicted by t-PA (odds ratio, 1.30). Both coefficients were rendered insignificant after additional adjustment for fasting glucose, and a correlation between renin and type 2 diabetes was revealed (hazard ratio, 0.79). A risk model including IL-1ra, t-PA, and the Framingham Offspring Study type 2 diabetes score was suggested, but prediction improvement was not significantly better than with the type 2 diabetes score only (difference in C-index, 0.02).

"In conclusion, proteomic blood profiling indicated cathepsin D as a new IR biomarker and suggested a causal effect of IR on t-PA," the authors write.

One author disclosed financial ties to Merck.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths